Gain Therapeutics (GANX) Expected to Announce Earnings on Wednesday

Key Points

• Gain Therapeutics will report Q1 2026 results before the market opens on May 13; analysts project an EPS loss of ($0.13) and revenue of $0.033M, and the company will host a conference call at 4:00 PM ET.
• GANX trades around $1.87 with a market cap of about $79.8M and strong liquidity (current ratio 6.63); analysts' views are mixed—a consensus "Moderate Buy" with a $8.50 price target contrasts with a recent Weiss Ratings "sell (d-)" note.
• Gain is a clinical-stage biotech leveraging its proprietary AlphaTarget platform to develop small-molecule allosteric modulators, with lead candidate GT-022 targeting Gaucher disease.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) is expected to post its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Gain Therapeutics to post earnings of ($0.13) per share and revenue of $0.0330 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.03. On average, analysts expect Gain Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gain Therapeutics Stock Performance

Shares of GANX stock opened at $1.87 on Wednesday. The stock's 50-day moving average is $2.16 and its two-hundred day moving average is $2.39. The firm has a market cap of $79.76 million, a price-to-earnings ratio of -3.07 and a beta of 0.15. Gain Therapeutics has a 1 year low of $1.41 and a 1 year high of $4.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.63 and a current ratio of 6.63.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of Gain Therapeutics in a research note on Friday, April 10th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.50.

Institutional Investors Weigh In On Gain Therapeutics

Hedge funds have recently made changes to their positions in the business. Sprott Inc. acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth about $39,000. Commonwealth Equity Services LLC acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth about $41,000. Millennium Management LLC acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth about $45,000. JPMorgan Chase & Co. acquired a new stake in shares of Gain Therapeutics during the third quarter worth about $47,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Gain Therapeutics during the fourth quarter worth about $47,000. Institutional investors and hedge funds own 11.97% of the company's stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.